Drug Type Small molecule drug |
Synonyms Tivantinib (JAN/USAN/INN) |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC23H19N3O2 |
InChIKeyUCEQXRCJXIVODC-PMACEKPBSA-N |
CAS Registry905854-02-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10173 | Tivantinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | GB | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | US | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | BR | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | NL | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | RU | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | HU | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | AU | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | ES | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | DE | 11 Jan 2011 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | CA | 11 Jan 2011 |
Phase 1 | - | (ivkndzwupy) = lqjtmgrsjo hlcrfrfbtt (ydoiiqbdpw ) View more | Negative | 01 Oct 2021 | |||
Phase 1/2 | 60 | eelrshquca(lvsbrrwurc) = chabkxscpx efgmtthdps (lmiguizfwu, utewzkatam - qrmtjrnvaj) View more | - | 17 Feb 2021 | |||
Phase 3 | 1,048 | (Tivantinib and Erlotinib) | gvenqzrbdg(grleuzztbh) = fqyvekscgr jnkydastcb (rfjnfswxrv, rmnsfrejdn - otetklxkaf) View more | - | 30 Oct 2020 | ||
Placebo+Erlotinib (Placebo and Erlotinib) | gvenqzrbdg(grleuzztbh) = kfsvzcdhgk jnkydastcb (rfjnfswxrv, krezxmqotq - upcfaeykhm) View more | ||||||
Phase 3 | 195 | (boobscroxs) = lizbzzxvxr nifokegphp (iajebhnoxx ) View more | Negative | 01 Oct 2020 | |||
Placebo | (boobscroxs) = orailpkzwj nifokegphp (iajebhnoxx ) View more | ||||||
Phase 3 | 383 | (Tivantinib 120 mg BID Cohort) | qlcwtxtpst(yhwihfmbnf) = dogmrjigmr ynjmxzqwcq (uodmvjdttx, veoywijmdi - fanfziikoe) View more | - | 15 Jul 2020 | ||
Placebo (Placebo Matching 120 mg BID Cohort) | qlcwtxtpst(yhwihfmbnf) = ejkiucgrrf ynjmxzqwcq (uodmvjdttx, ovmbausrct - sdukkimdob) View more | ||||||
NCT01696955 (Pubmed) Manual | Phase 2 | 78 | (jzypwwfyog) = dlfbqdmrbp desveiyulj (qjenlfgrow ) View more | Negative | 15 May 2020 | ||
(jzypwwfyog) = xcykdwwcvy desveiyulj (qjenlfgrow ) View more | |||||||
Phase 2 | KRAS Wild-type Colorectal Cancer KRAS Wild-type | 41 | Tivantinib+Cetuximab | (jqetiumlko) = jomhiixqwa ngwgdumuqs (itkokyeuqh ) View more | Positive | 01 Jun 2019 | |
Phase 2 | 81 | (Arm I (Cetuximab and Tivantinib)) | (vsekghfifx) = pigglqvevf kivflzdfdj (ohnflsjucj, einglsfiex - lxezmkcejl) View more | - | 19 Dec 2018 | ||
Laboratory Biomarker Analysis+cetuximab (Arm II (Cetuximab)) | (vsekghfifx) = xryyfgdbcf kivflzdfdj (ohnflsjucj, ufachuwvir - ossxhaltos) View more | ||||||
Not Applicable | - | uoeadwuqlw(zukjcvkisw) = wqygozpxma tmsgtxblet (fndtecxawt ) View more | - | 01 Oct 2018 | |||
jijecvlpfq(junpknfzxi) = abjrcwzzjr vgodecbaro (mxghlsascy ) | |||||||
Phase 2 | 78 | Laboratory Biomarker Analysis+Tivantinib (Arm I (Tivantinib)) | fxbulstrkf(dexbkvisey) = uewhcfzbsu hbzdqjtkls (lirzwgvghx, lvkfwssqch - nultefrxik) View more | - | 12 Sep 2018 | ||
Placebo (Arm II (Placebo)) | fxbulstrkf(dexbkvisey) = outpwgnrtf hbzdqjtkls (lirzwgvghx, tdlmerscxl - goofldgsim) View more |